Table D24. Morbidity outcomes 3

| Author, Year  Trial Name | Morbidity Outcome 3 | Description of Timing of Measurement of Outcome | Data source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Bogner et al., 20084 NA | Diastolic BP, mean (SD), mm Hg - compared at 6 weeks | measured at baseline and at 6 weeks | automated BP monitor | G1: 32 G2: 32 | G1: 75.8 (10.7) G2: 85.0 (11.9) 95% CI,  p: .002 |
| Choudhry et al., 201113 MI FREEE | First fatal or nonfatal vascular event | NA | health claims data | G1: 2845 G2: 3010 | G1: 329 patients; 11.0 per 100 person-years G2: 405 patients; 12.8 per 100 person-years  Adjusted hazard ratio: 0.86, 95% CI, 0.74-0.99 p: 0.03 |
| Janson et al., 200320 NA | Perceived control of asthma at week 7; between group difference in change from baseline to final visit at week 7 (95% CI) | timeframe of measure not reported; measured at each study visit | questionnaire | G1: 33 G2: 32 | G1: 42 (5) G2: 42 (5) Between group difference: 2.6 (0.1 to 5), p= 0.04 |
| Janson et al., 200921  NA | Mean change Eosinophil cationic protein (ECP) (nanograms/mL);  Eosinophils > 0% (> 1/500 cells), During intervention(T0-T1), following intervention (T1-T2), and for entire study duration (T0-T2) | collected once at the end of each time period; During intervention(T0-T1), following intervention (T1-T2), and for entire study duration (T0-T2) | sputum sample | G1: 45  G2: 39 | **T0-T1**  G1: 0.88  G2: 1.05  p: 0.55  **T1-T2**  G1: 0.88 G2: 1.11  95% CI,  p: .44  **T0-T2**  G1: 0.77  G2: 1.17  p: 0.18  Odds Ratios of >0%  ECP  **T0-T1**:  G1: 0.5  G2: 1.0  p: 0.4  **T1-T2**:  G1: 3.1  G2: 0.6  p: 0.09  **T0-T2:**  G1: 1.7  G2: 0.6  p: 0.29 |
| Katon et al., 200128 NA  Ludman et al., 200329 NA  Van Korff et al., 200330 NA | Functional impairment   (Von Korff et al.) | BL, 3, 6, 9, 12 months | Self-report, SF-36 Social functioning Scale( using imputed data and adjusting for age, sex, chronic disease score, neuroticism, and baseline SCL) | **BL** G1: 194 G2: 192  **3 mos** G1: 186 G2: 186  **6 mos** G1: 181 G2: 170  **9 mos** G1: 175 G2: 164  **12 mos** G1: 174 G2: 153 | **3 mos** mean (SD) G1: 81.4 (20.5) G2: 81.1 (21.1)  95% CI, NR  p: NR  **6 mos** mean (SD) G1: 83.3 (20.2) G2: 83.0 (20.9) 95% CI, NR  p: NR  **9 mos** mean (SD) G1: 84.7 (19.7) G2: 81.4 (22.4)  95% CI, NR  p: NR  **12 mos** mean (SD) G1: 86.9 (17.8) G2: 81.7 (20.4) 95% CI, NR  p: NR  Effects: Intervention Estimate: 0.27 (1.42) T-statistic: 0.19 p: 0.85  Time Estimate: 0.66 (0.48) T-statistic: 1.38 p: 0.17  Intervention x time Estimate: 1.31 (0.66) T-statistic: 1.98 p: 0.047 |
| Katon et al., 199625  NA | 50% or more improvement on IDS | 4-month follow up | IDS | G1: 77  G2: 76 | Major Depression Group  (% showing >50% improvement)  G1: 74.1%  G2: 42.3%p:0.02  No significant differences between G1 and G2 in the minor depression group  G1: 51.3%  G2: 52.8%  p: 0.90 |
| Lin et al., 200632  NA | Adjusted mean BMI difference (baseline minus endpoint) | NA | NR | **BL** G1: 164 G2: 165  **EP** G1: 164 G2: 165 | **BL** (kg/m^2) = NA 95% CI, NA p: NA  **EP** (kg/m^2) = 0.70 95% CI, 0.17 to 1.24 p: <0.01 with adjustment |
| Pearce et al., 200839  Cardiovascular Risk Education and Social Support (CaRESS) Trial | Mean LDL cholesterol level | 6 times over a 12-month period | Phlebotomy during study practice site visits | BL G1 + G2: 24  G3: 16 Midpoint G1 + G2: 18 G3: 11 Endpoint G1 + G2: 18 G3: 11 | **BL** G1 + G2: 137.0  G3: 137.3 95% CI, NR p (G1 + G2 vs. G3): 0.9471 (unadjusted), NA (adjusted)  **Midpoint** G1 + G2: 139.4 G3: 130.5 95% CI, NR p (G1 + G2 vs. G3): 0.6716 (unadjusted), NA (adjusted)  **EP** G1 + G2: 135.4 G3: 110.6 95% CI, NR p (G1 + G2 vs. G3): 0.3238 (unadjusted), NA (adjusted) |
| Schaffer et al., 200447  NA | PQAQ(higher=better): mean | baseline, 3, 6 months; timeframe: specific to time of measurement | questionnaire | G1: 11  G2: 10  G3: 12 G4: 13 | G1: Pre: 43.72 (5.14)  3 mo: 49.90 (4.6)  6 mo: 43.33 (14.43)  G2: Pre: 42.70 (6.696)  3 mo: 44.0 (4.97)  6 mo: 44.20 (6.16)  G3 :Pre: 44.50 (4.62)  3 mo: 45.75 (6.27)  6 mo: 43.33 (14.44)  G4:Pre: 44.61 (6.47)  3 mo: 44.67 (6.82)  6 mo: 45.27 (5.57)  Pre-3: G4 vs. G2 p = .8  G4 vs. G1 p = .6 G4 vs. G3 p = .3 Pre-6  G4 vs. G3 p = .2  G4 vs. G2 p = .4  G4 vs. G1 p = .8 |
| Schneider et al., 200849  NA | Occurrence of angina | 6 and 12 months for the past 6 months | Medical chart review | G1: 47  G2: 38 | G1: NR  G2: NR  95% CI, NR  p: NR  Numbers not reported, but results were not significant |
| Wilson et al., 201065  Better Outcomes of Asthma Treatment (BOAT | Change in Asthma control; | measured baseline and at FU year 1; measured for the preceding 4 weeks and reported as change in ATAQ score | Asthma Therapy Assessment Questionnaire (ATAQ); 4-item scale. | G1: 182  G2: 180  G3: 189 | Change in ATAQ score  G1: -.80  G2: -.54  G3: -.46  ATAQ =0 (no asthma control problems)  G1:G3 OR: 1.9  95% CI, 1.3-2.9  p-0.002  G2:G3 OR: 1.6  95% CI, 1.1-2.4  p=0.0239 |